Methamphetamine cue-reactivity and cognitive reappraisal in men with methamphetamine use disorder
Official title: Cue Reactivity Modulation in MSM With Methamphetamine Use Disorder
Run by Icahn School of Medicine at Mount Sinai · NCT07086014 · Data updated 2026-11-12
This project will test whether cognitive reappraisal reduces methamphetamine cue-triggered brain and physiological responses during abstinence in men with methamphetamine use disorder and whether effects differ between men who have sex with men (MSM) and non-MSM.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 60 Years |
| Sex | Men only |
| Enrollment | 88 (estimated) |
| Sponsor | Icahn School of Medicine at Mount Sinai Academic / other |
| Locations | 1 site (New York, New York) |
| Status | Recruiting |
| Started | August 19, 2024 |
| Main results expected | August 30, 2025 |
| Study ends | August 30, 2025 |
| Registry record updated | July 25, 2025 |
| Trial ID | NCT07086014 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are males aged 18–60 with a DSM-5 diagnosis of methamphetamine use disorder who identify as MSM or non-MSM and meet the study's abstinence windows (about 1–3 weeks for current users or ~2–4 months for abstinent participants).
✕Probably not a fit
Women, people outside the 18–60 age range, individuals whose primary drug is not methamphetamine, and those unable to meet required abstinence or in-person visit requirements are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
In a two-year observational cohort at the Mount Sinai Addiction Institute, researchers will record psychophysiological responses (including EEG, focusing on the LPP) and craving to methamphetamine-related cues and follow participants across specified abstinence windows. Men aged 18–60 with DSM-5 methamphetamine use disorder who identify as MSM or non-MSM will be enrolled and stratified by current versus abstinent status to examine incubation of cue-reactivity over time. Cognitive reappraisal use and training will be measured to see if reductions in cue-elicited EEG and craving accompany regulation, and associations with clinical outcomes will be tracked. The study will compare group differences between MSM and non-MSM to determine whether biomarkers or reappraisal effects vary by sexual orientation.
Why it matters
Potential benefit: If successful, the study could identify a measurable brain-based marker of methamphetamine craving and show that cognitive reappraisal lowers cue-reactivity, informing targeted relapse-prevention strategies for men with MUD.
How similar studies have gone: Previous work in cocaine use disorder and smoking has shown that cognitive reappraisal can reduce cue-reactivity and craving and preliminary EEG studies have demonstrated LPP reductions, but applying these measures specifically to methamphetamine use and to MSM versus non-MSM comparisons is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Ability to understand and give informed consent * Identify as either MSM or non-MSM * Males; Age 18-60 * DSM-5 Diagnosis of MUD (Methamphetamine Use Disorder) * Have appropriate abstinence duration \[i.e., current Methamphetamine users (MA): 2 weeks (range: 1-3 weeks); MA-abstinent: 3 months (range: 2-4 months)\] * Treatment-seeking MUD must be in a treatment facility for substance use disorder, with MA as the primary drug (at the first visit) * Treatment-seeking MUD must be abstinent from MA use for approximately 2 weeks (range: 1-3 weeks) at enrollment. Exclusion Criteria: • Women
Where it's running
-
Icahn School of Medicine at Mount Sinai
New York, New York, United States Recruiting
Study contacts
- Principal investigator: Muhammad A Parvaz, PhD — Icahn School of Medicine at Mount Sinai
- Study coordinator: Muhammad A Parvaz
- Email: muhammad.parvaz@mssm.edu
- Phone: 212-241-3638
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Tirzepatide for methamphetamine use disorder (phase 2)
This phase 2 trial tests whether weekly tirzepatide injections can help adults with moderate to severe methamphetamine use disorder reduce use and improve outcomes compared with placebo.
-
Psilocybin Therapy for MeUD and HIV
This study tests whether a single psilocybin dose, paired with motivational support therapy, can help people with HIV and moderate-to-severe methamphetamine use disorder stop using methamphetamine.
-
ECG changes in adults using methamphetamine with and without psychosis
This project will see if heart ECG measurements differ between adults hospitalized for methamphetamine use who have psychosis and those who do not.
-
Benefits of reducing methamphetamine use
This study will try contingency management to see if cutting back on methamphetamine improves physical, mental, and social health for adults with moderate-to-severe methamphetamine use disorder.
-
CHAMPION: Combining HIV Prevention and Meth Treatment for HIV-Negative MSM
This pilot test will see if two mobile health tools can help HIV-negative men who have sex with men who use meth take PrEP more consistently.
-
Troriluzole and methamphetamine response
This study will see if taking troriluzole changes how methamphetamine affects adults with methamphetamine use disorder.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.